Plaintiffs Fight Privilege Claim In Neurontin Case

By Ben James

Law360, New York (February 22, 2010, 2:13 PM ET) -- Direct purchaser plaintiffs accusing Pfizer Inc. and a subsidiary of blocking generic competition for the epilepsy drug Neurontin by filing baseless patent litigation want a federal judge to look for evidence of crime or fraud in documents allegedly covered by attorney-client privilege.

Louisiana Wholesale Drug Co. Inc. and Meijer Inc. filed their motion for discovery pursuant to the crime-fraud exception in the U.S. District Court for the District of New Jersey on Friday.

The plaintiffs said they have put forth a "sufficient and good faith basis"...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles